Aspergillus viridinutans: An agent of adult chronic invasive aspergillosis

Medical Mycology

Volumn 49, Issue 7, 2011, Pages 755-759

  Coelho, Danina ^a   Silva, Susana ^a   Vale Silva, Luís ^b   Gomes, Helena ^a   Pinto, Eugénia ^b   Sarmento, António ^a   Pinheiro, Maria Dolores ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

adult patient; antifungal susceptibility; Aspergillus viridinutans; fungal genotyping; invasive aspergillosis

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; CASPOFUNGIN; CLAVULANIC ACID; ETANERCEPT; ITRACONAZOLE; METFORMIN; METHOTREXATE; POSACONAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLUS; ASPERGILLUS VIRIDINUTANS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEVER; FUNGUS IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; INVASIVE ASPERGILLOSIS; LUNG NODULE; LYMPHADENOPATHY; MALE; MINIMUM INHIBITORY CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RHEUMATOID ARTHRITIS; SYMPTOM; THORAX PAIN;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS; CHRONIC DISEASE; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; NEUROASPERGILLOSIS; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED;

ASPERGILLUS VIRIDINUTANS;

EID: 80052558203     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.556672     Document Type: Article

References (20)

1. Hope WW, Denning DW. Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clin Microbiol Infect 2004; 10 : 2-4. (Pubitemid 38128586)
2. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67 : 1567-1601. (Pubitemid 47267298)
3. Krishnan S, Manavathu EK, Chandrasekar PH. A spergillus fl avus : an emerging non- fumigatus Aspergillus species of signifi cance. Mycoses 2009; 52 : 206-222.
4. Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE. A spergillus niger : an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol 2010; 59 : 834-838.
5. Sugui JA, Vinh DC, Nardone G, et al. N eosartorya udagawae ( Aspergillus udagawae ), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus ? J Clin Microbiol 2010 48 : 220-228.
6. McLennan EI, Tucker SC, Thrower LB. New soil fungi from Australian heathland: Aspergillus , Penicillium , Spegazzinia . Austral J Bot 1954; 2 : 355-364.
7. Varga J, Tó th B, Rigó K, Debets F, Kozakiewicz Z. Genetic variability within the Aspergillus viridinutans species. Folia Microbiol (Praha) 2000; 45 : 423-428.
8. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati : antifungal susceptibility patterns and sequence-based identifi cation. Antimicrob Agents Chemother 2008; 52 : 1244-1251. (Pubitemid 351521983)
9. Katz ME, Dougall AM, Weeks K, Cheetham BF. Multiple genetically distinct groups revealed among clinical isolates identifi ed as atypical Aspergillus fumigatus . J Clin Microbiol 2005; 43 : 551-555. (Pubitemid 40255999)
10. Yaguchi T, Horie Y, Tanaka R, et al. Molecular phylogenetics of multiple genes on Aspergillus section Fumigati isolated from clinical specimens in Japan. Nip Ishinkin Gakkai Zasshi 2007; 48 : 37-46. (Pubitemid 46280133)
11. Vinh DC, Shea YR, Jones PA, et al. Chronic invasive aspergillosis caused by Aspergillus viridinutans . Emerg Infect Dis 2009; 15 : 1292-1294.
12. Sigler L, Kennedy MJ. A spergillus, F usarium, and other opportunistic moniliaceous fungi. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC,Yolken RH (eds.) Manual of Clinical Microbiology , 7th edn. Washington, DC: ASM Press, 1999: 1212-1241.
13. Clinical and Laboratory Standard Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fung i; approved standard. Document M38-A2, 2nd edn, Wayne, PA: CLSI, 2008.
14. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Inf Dis 2008; 46 : 327-360. (Pubitemid 351265310)
15. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46 : 2568-2572.
16. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 2008; 61 : 616-620. (Pubitemid 351321136)
17. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and fi lamentous fungi. Antimicrob Agents Chemother 2006; 50 : 917-921. (Pubitemid 43327795)
18. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fl uconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50 : 2009-2015. (Pubitemid 43807519)
19. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and fi lamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52 : 3637-3641.
20. European Committee for Antimicrobial Susceptibility Testing. Methodfor the determination of broth dilution MICs of antifungal agents for conidia forming moulds. Defi nitive document E.DEF9.1, 2008. www.eucast.org